Hypermarcas wants to make alliances with pharmaceutical

The manufacturer of medicines and consumer products study strategic alliances in the area Hypermarcas pharmaceutical, said yesterday the company's Chairman, Claudio Bergamo. "It's not for the very short term, but it's a path we are looking beyond organic growth," said the Executive, during annual presentation to analysts and investors.
"Recently we traveled to India to meet potential partners and new markets," he said. According to Bergamo, indiana industry has 45% of the American market to generics. He cited, among the main companies: Glenmark, Cipla, Cadila, Dr. Reddy's, Ranbaxy and Sun Pharmaceutical. "We saw on this trip that when companies understand what is Hypermarcas, saw the great potential of sharing technology." Only about 20% of the revenue of these companies is generated in India, according to Bergamo. "Many of them tried to do business in Brazil and, for the most part, came to the conclusion that the entry barrier is too large. They lost a lot of money here and they said the only people in Brazil with someone who knows the market. "
Alliances with international industries are evaluated as part of the company's strategy to fill blanks in the pharmaceutical market. Hypermarcas competes in 51% of all kinds of medicines available in the Brazilian market and wants to reach 78% in three to five years. To do this, is developing more drugs. "But we also want to bring products that exist out there and are not yet in Brazil," said Bergamo.
Hypermarcas is a leader in the Brazilian market of OTC medicines (non-prescription), with brands such as Gelol, Rinosoro, Apracur, Atroveran and Benegrip. The company is the runner-up in the segment RX (prescription), behind Novartis, and third in generics, after EMS and Sanofi.
Luiz Violland, President of the pharmaceutical division Hypermarcas, said the company wants to grow in vitamins-category in which has 27% of sales and can reach 80%-, diabetes drugs and for the nervous system.
Bergamo told the manufacturer control block has discussed to what extent the name Hypermarcas translates what the company is today. The name was adopted in 2007, when the company began a series of acquisitions-were 23, until 2010. Currently, 65% of the business segment are considered Hypermarcas pharmacist. This percentage includes preservatives, sweeteners and sunscreens. Such categories are managed by the company's Consumer Division, but according to Bergamo, are classified as pharmaceutical products.
The other 35% of businesses refer to products of hygiene and beauty. According to Bergamo, just 15% of the total revenue Hypermarcas, however, would be impacted by a possible increase of the tax burden on the cosmetics industry. Report of the "Folha de s. Paulo" yesterday reported that the new economic team of the President Dilma Rousseff studies raise the rate of PIS/Cofins on imported and increase taxation to the cosmetics industry in 2015, to balance the public accounts. The value was informed in February that the Government was studying that possibility, but the Ministry of finance promised in April that would consult the industry before a decision. The President of the National Association of industries of hygiene and cosmetics, João Carlos Basilio, said yesterday that there has been no recent meeting with the Government. "I believe that anything will be valid only in 2016," said Bergamo. Hypermarcas closed shares falling 4.7 percent yesterday. The roles of Natura, industry leader, retreated 5.2 percent.